首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1775441

全球抗癌藥物市場：2025-2030 年預測

Global Oncology Drug Market - Forecasts from 2025 to 2030

出版日期: 2025年06月27日 | 出版商:

Knowledge Sourcing Intelligence | 英文 141 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球癌症治療市場預計將從 2025 年的 3,157.78 億美元成長到 2030 年的 4,435.95 億美元，複合年成長率為 7.03%。

本研究報告對癌症治療市場進行了全面分析，為行業專業人士提供有關市場趨勢、技術進步和競爭動態的關鍵見解。該研究探討了癌症治療領域不斷發展的格局，重點在於治療類型、癌症類型、分銷管道和區域格局。報告旨在提供可操作的數據，幫助相關人員應對這一快速成長領域的複雜格局。

市場概況和範圍

該研究將腫瘤藥物定義為用於治療各種癌症的藥物，並分析了其市場結構。研究涵蓋化療、標靶治療、荷爾蒙治療、生物相似藥和其他新興療法。市場按癌症類型細分，包括肺癌、大腸癌、攝護腺癌、血液癌、乳癌、肝癌、子宮頸癌和卵巢癌。荷爾蒙療法還分析了分銷管道，包括醫院藥房、零售藥房、線上藥房和專科診所，並按地理分類了北美、南美、歐洲、中東和非洲以及亞太地區。廣泛的覆蓋範圍使行業專家能夠全面了解市場動態。

商業和技術見解

該研究明確了市場促進因素，例如癌症發病率上升和個人化醫療的進步，以及限制因素，例如高昂的開發成本和監管障礙，並深入探討了商業前景。波特五力分析和產業價值鏈評估支持了包括免疫療法和生物相似藥成長在內的機會。技術展望部分探討了精準腫瘤學和人工智慧主導的藥物研發等正在重塑治療模式並改善治療效果的創新技術。

競爭格局與分析

抗癌藥物市場研究聚焦競爭格局，深入檢驗主要企業及其策略。研究內容包括市場佔有率分析、競爭態勢分析，以及對影響產業發展的併購和聯盟的洞察。主要企業的顯著發展凸顯了市場的動態：

羅氏公司（F. Hoffmann-La Roche Ltd.）正憑藉免疫療法領域的進展，尤其是PD-L1抑制劑阿特珠單抗（Atezolizumab）的研發，鞏固其市場地位。 2024年，羅氏公司獲得監管部門核准，推出一種針對非小細胞肺癌的新型聯合治療，進一步擴大了其產品組合，鞏固了其在免疫療法領域的市場地位。
默克公司憑藉其重磅PD-1抑制劑帕博利珠單抗（ Pembrolizumab）繼續引領免疫治療領域。默克宣布與一家生技公司達成策略合作，計劃於2025年開發針對乳癌和大腸癌的新一代抗體藥物偶聯物（ADC）。此舉凸顯了默克致力於多元化腫瘤產品線，並利用夥伴關係關係加速創新的決心，使公司在競爭中佔據優勢。

這些發展表明，研發重點的增加和策略聯盟的建立正在推動抗癌藥物市場的競爭。《抗癌藥物市場研究》對此類活動進行了詳細分析，使行業專業人士能夠預測市場變化並尋找合作機會。

細分和地理洞察

該研究根據治療方法類型對市場進行了細分，其中免疫療法和標靶治療因其療效和特異性而日益普及。根據癌症類型，肺癌和乳癌因其高發病率而佔據主導地位，而肝癌和子宮頸癌則在新興市場中提供了成長機會。分銷管道分析顯示，受數位化和患者便利性的推動，尤其是在北美和歐洲，人們正在轉向線上藥局。根據地區分類，北美憑藉其先進的醫療基礎設施引領市場，而亞太地區則因中國和印度醫療投資的增加而呈現快速成長。

策略建議

這項關於抗癌藥物市場的研究為相關人員提供了策略建議，幫助他們專注於投資新型治療方法的研發，並拓展亞太等高成長地區。業界專業人士可以藉鏡本研究的洞見，調整策略以順應市場趨勢，利用技術進步，並有效應對競爭壓力。

本報告的主要優點

深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
競爭格局：了解主要企業採用的策略策略，並了解正確策略的市場滲透潛力。
市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
可行的建議：利用洞察力來提供策略決策，在動態環境中開闢新的業務流和收益。
受眾範圍廣：對於新興企業、研究機構、顧問、中小企業和大型企業來說都是有益且具成本效益的。

它有什麼用途？

產業與市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

實際數據為2022年至2024年，預測數據為2025年至2030年
成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
競爭定位、策略和市場佔有率分析
收益成長和預測細分市場和區域分析（包括國家）
公司概況（策略、產品、財務、主要發展等）

The Oncology Drug Market Study provides a comprehensive analysis of the global oncology drug market, offering industry experts critical insights into market trends, technological advancements, and competitive dynamics. This study examines the evolving landscape of cancer treatment, focusing on therapy types, cancer types, distribution channels, and geographic regions. It aims to equip stakeholders with actionable data to navigate the complexities of this rapidly growing sector.

Market Overview and Scope

The Oncology Drug Market Study explores the market's structure, defining oncology drugs as pharmaceutical interventions designed to treat various cancers. The study encompasses chemotherapy, targeted therapy, immunotherapy, hormone therapy, biosimilars, and other emerging treatments. It segments the market by cancer type, including lung, colorectal, prostate, blood, breast, liver, cervical, and ovarian cancers, among others. Distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics are analyzed, alongside a geographic breakdown covering North America, South America, Europe, the Middle East and Africa, and Asia Pacific. This broad scope ensures a holistic understanding of market dynamics for industry professionals.

Business and Technological Insights

The study delves into the business landscape, identifying key market drivers such as rising cancer prevalence and advancements in personalized medicine, alongside restraints like high development costs and regulatory hurdles. Opportunities, including the growth of immunotherapy and biosimilars, are highlighted, supported by a Porter's Five Forces analysis and an industry value chain assessment. The technological outlook section explores innovations like precision oncology and AI-driven drug discovery, which are reshaping treatment paradigms and enhancing therapeutic outcomes.

Competitive Environment and Analysis

In the Oncology Drug Market Study, the competitive environment is a focal point, offering a detailed examination of major players and their strategies. The study includes a market share analysis, a competitive dashboard, and insights into mergers, acquisitions, and collaborations shaping the industry. Notable developments from key players underscore the dynamic nature of the market:

F. Hoffmann-La Roche Ltd. has strengthened its position through advancements in immunotherapy, particularly with its PD-L1 inhibitor, atezolizumab. In 2024, Roche expanded its portfolio by securing regulatory approval for a new combination therapy targeting non-small cell lung cancer, enhancing its market presence in the immunotherapy segment. This development reflects Roche's strategic focus on precision medicine and combination therapies to address unmet needs in oncology.
Merck & Co., Inc. continues to lead in the immunotherapy space with pembrolizumab, a blockbuster PD-1 inhibitor. In 2025, Merck announced a strategic collaboration with a biotech firm to develop next-generation antibody-drug conjugates (ADCs) for breast and colorectal cancers. This move highlights Merck's commitment to diversifying its oncology pipeline and leveraging partnerships to accelerate innovation, positioning it as a formidable player in the competitive landscape.

These developments illustrate the intense R&D focus and strategic alliances driving competition in the oncology drug market. The Oncology Drug Market Study provides a granular analysis of such activities, enabling industry experts to anticipate market shifts and identify collaboration opportunities.

Segmentation and Geographic Insights

The study segments the market by therapy type, with immunotherapy and targeted therapies gaining traction due to their efficacy and specificity. By cancer type, lung and breast cancer segments dominate due to high incidence rates, while liver and cervical cancers present growth opportunities in emerging markets. Distribution channel analysis reveals a shift toward online pharmacies, particularly in North America and Europe, driven by digitalization and patient convenience. Geographically, North America leads due to advanced healthcare infrastructure, while Asia Pacific shows rapid growth fueled by increasing healthcare investments in China and India.

Strategic Recommendations

The Oncology Drug Market Study offers strategic recommendations for stakeholders, emphasizing investment in R&D for novel therapies and expansion into high-growth regions like Asia Pacific. Industry experts can leverage the study's insights to align their strategies with market trends, capitalize on technological advancements, and navigate competitive pressures effectively.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2022 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Key Market Segmentation

By Therapy Type

Chemotherapy
Targeted Therapy
Immunotherapy
Hormone Therapy
Biosimilars
Others

By Type of Cancer

Lung Cancer
Colorectal Cancer
Prostate Cancer
Blood Cancer
Breast Cancer
Liver Cancer
Cervical and Ovarian Cancer
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Clinics and Cancer Centers

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
South Korea
India
Thailand
Taiwan
Indonesia
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. ONCOLOGY DRUG MARKET BY THERAPY TYPE

5.1. Introduction
5.2. Chemotherapy
5.3. Targeted Therapy
5.4. Immunotherapy
5.5. Hormone Therapy
5.6. Biosimilars
5.7. Others

6. ONCOLOGY DRUG MARKET BY TYPE OF CANCER

6.1. Introduction
6.2. Lung Cancer
6.3. Colorectal Cancer
6.4. Prostate Cancer
6.5. Blood Cancer
6.6. Breast Cancer
6.7. Liver Cancer
6.8. Cervical and Ovarian Cancer
6.9. Others

7. ONCOLOGY DRUG MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction
7.2. Hospital Pharmacies
7.3. Retail Pharmacies
7.4. Online Pharmacies
7.5. Specialty Clinics and Cancer Centers

8. ONCOLOGY DRUG MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others